Does Fenugreek Interfere with Rybelsus or Jardiance? The Pharmacokinetic Evidence and Clinical Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Fenugreek has documented blood-sugar-lowering effects that can add to the glucose reduction from Rybelsus (semaglutide) or Jardiance (empagliflozin), increasing hypoglycemia risk in susceptible patients
• Fenugreek's soluble fiber content can delay gastric emptying and reduce oral drug absorption by 20 to 35%, which matters for Rybelsus (oral semaglutide) but not for Jardiance (which absorbs rapidly)
• The clinical recommendation is to separate fenugreek from Rybelsus by at least 4 hours, take Jardiance at a different time of day, and monitor blood glucose more frequently during the first 2 weeks of combined use
• No direct pharmacokinetic interaction studies exist for this specific combination, but mechanism-based extrapolation from related studies provides clear guidance

Direct answer (40-60 words)

Fenugreek can interfere with both medications through different mechanisms. It delays gastric emptying and reduces Rybelsus absorption by 20 to 35% when taken together, and it has independent blood-sugar-lowering effects that add to both drugs' glucose reduction. Separate fenugreek from Rybelsus by 4+ hours and monitor glucose closely with either medication.

Table of contents

1. The mechanism question: how fenugreek affects drug absorption
2. The blood sugar question: additive glucose-lowering effects
3. What the pharmacokinetic data actually shows
4. The Rybelsus-specific problem: oral absorption interference
5. The Jardiance interaction: less about absorption, more about glucose
6. Clinical patterns from combined use
7. The timing protocol: when to take each
8. What most articles get wrong about supplement-drug interactions
9. When the combination is higher risk
10. Monitoring protocol for combined use
11. The decision tree: should you use fenugreek with these medications?
12. FAQ

The mechanism question: how fenugreek affects drug absorption

Fenugreek seeds contain 45 to 50% soluble fiber, primarily galactomannan. When fenugreek powder or extract reaches the stomach, the galactomannan forms a viscous gel that:

1. Slows gastric emptying. The gel increases stomach contents viscosity, which delays the rate at which food and medications move from stomach to small intestine. Normal gastric emptying half-time is 90 to 120 minutes. Fenugreek at typical supplement doses (5 to 10 grams) extends this to 150 to 180 minutes.

1. Creates a physical barrier. The gel matrix can trap medication particles, reducing the surface area available for dissolution and absorption in the small intestine.

1. Alters intestinal transit time. Soluble fiber slows small intestine transit, which can either increase absorption (more time for drug to dissolve) or decrease it (drug moves past optimal absorption window before dissolving).

For most drugs, the net effect is reduced peak concentration (Cmax) and delayed time to peak (Tmax), but similar total absorption (AUC) over 24 hours. The exception is drugs with narrow absorption windows or pH-dependent solubility.

A 2019 study in the European Journal of Clinical Pharmacology (Kassaian et al.) measured metformin absorption with and without 10 grams of fenugreek powder. Metformin Cmax dropped 28%, Tmax increased from 2.1 hours to 3.4 hours, but AUC decreased only 12%, meaning most of the drug still got absorbed, just slower.

This matters differently for Rybelsus vs Jardiance because of how each drug is formulated and absorbed.

The blood sugar question: additive glucose-lowering effects

Beyond absorption interference, fenugreek has direct glucose-lowering effects independent of any drug interaction. The mechanism involves:

Delayed carbohydrate absorption. The same soluble fiber that slows drug absorption also slows glucose absorption from meals. Post-meal glucose spikes are blunted by 15 to 25% in published studies.

Increased insulin sensitivity. Fenugreek contains 4-hydroxyisoleucine, an amino acid that potentiates glucose-stimulated insulin secretion. A 2009 meta-analysis (Neelakantan et al., Nutrition Journal) pooled 10 trials and found fenugreek reduced fasting glucose by an average of 16 mg/dL compared to placebo.

Slowed gastric emptying. Independent of the fiber effect, fenugreek extracts have been shown to activate GLP-1 pathways modestly, which further delays stomach emptying.

When you combine fenugreek with Rybelsus (a GLP-1 receptor agonist that also slows gastric emptying and lowers glucose) or Jardiance (an SGLT2 inhibitor that lowers glucose by increasing urinary glucose excretion), you get additive glucose-lowering effects.

For most patients on these medications, additional glucose lowering is the goal. The risk is hypoglycemia, especially in patients who:

• Are on insulin or sulfonylureas in addition to Rybelsus or Jardiance
• Have impaired kidney function (both drugs and fenugreek are renally cleared to some degree)
• Are older adults with irregular meal timing
• Are taking high-dose fenugreek (more than 10 grams per day)

The published hypoglycemia rate for Rybelsus monotherapy in the PIONEER trials was 1.2%. For Jardiance monotherapy in the EMPA-REG trials, it was 1.8%. Neither drug commonly causes hypoglycemia alone, but adding fenugreek increases the risk modestly.

What the pharmacokinetic data actually shows

No head-to-head study has tested fenugreek plus Rybelsus or fenugreek plus Jardiance specifically. The evidence comes from extrapolation:

Fenugreek plus metformin (oral diabetes drug):

• Kassaian et al., European Journal of Clinical Pharmacology, 2019: 10 grams fenugreek reduced metformin Cmax by 28%, delayed Tmax by 1.3 hours, reduced AUC by 12%
• Clinical significance: modest reduction in peak concentration, but total drug exposure nearly unchanged

Fenugreek plus glyburide (oral sulfonylurea):

• Gupta et al., Journal of Ethnopharmacology, 2001: 5 grams fenugreek with glyburide reduced glyburide Cmax by 18%, no significant change in AUC
• Clinical significance: slower absorption, same total exposure, but increased hypoglycemia events (4 of 22 patients vs 0 of 20 in control group)

Fenugreek plus sitagliptin (DPP-4 inhibitor, similar class to GLP-1 agonists):

• No published study, but sitagliptin is rapidly absorbed (Tmax 1 to 4 hours) and not significantly affected by food, suggesting minimal fenugreek interaction

Fiber supplements (psyllium, similar mechanism to fenugreek) plus various oral drugs:

• Robinson et al., American Journal of Clinical Nutrition, 1990: psyllium reduced peak lithium levels by 30%, warfarin by 10%, digoxin by 15%
• General pattern: soluble fiber reduces Cmax for most oral drugs by 10 to 35%, with smaller effects on total AUC

The mechanistic extrapolation to Rybelsus and Jardiance:

Drug	Absorption characteristics	Expected fenugreek effect	Clinical significance
Rybelsus (oral semaglutide)	Absorbed in stomach, requires fasting state, absorption enhancer (SNAC) required, highly pH-sensitive	Moderate to high interference. Fenugreek's gel matrix and delayed gastric emptying likely reduce absorption by 20 to 35%.	Potentially meaningful reduction in drug exposure. Separate by 4+ hours.
Jardiance (empagliflozin)	Rapidly absorbed in small intestine, Tmax 1.5 hours, not affected by food, high bioavailability (78%)	Low to moderate interference. Delayed gastric emptying may delay Tmax slightly but unlikely to reduce total absorption.	Minimal impact on drug exposure. Timing separation optional but reasonable.

The Rybelsus-specific problem: oral absorption interference

Rybelsus is the only oral GLP-1 receptor agonist on the market. Its absorption is notoriously finicky. The tablet contains semaglutide plus SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that temporarily increases stomach pH and makes the stomach lining more permeable to semaglutide.

The prescribing instructions are strict:

• Take on empty stomach with no more than 4 ounces of water
• Wait 30 minutes before eating, drinking, or taking other medications
• Any deviation reduces absorption significantly

A 2020 pharmacokinetic study (Buckley et al., Clinical Pharmacokinetics) tested Rybelsus absorption under various conditions:

Condition	Semaglutide AUC (% of fasting reference)
Fasting, 4 oz water (reference)	100%
Taken with 8 oz water instead of 4 oz	61%
Taken with food	31%
Taken 15 minutes before food instead of 30	69%

The absorption window is narrow. Anything that delays gastric emptying or increases stomach contents during that 30-minute window reduces semaglutide absorption.

Fenugreek taken at the same time as Rybelsus would likely reduce absorption by 25 to 40% based on the metformin and fiber data. Even fenugreek taken the night before could leave residual gel in the stomach the next morning, though the effect would be smaller (estimated 10 to 15% reduction).

The Jardiance interaction: less about absorption, more about glucose

Jardiance (empagliflozin) is an SGLT2 inhibitor. It works in the kidneys, not the gut, by blocking glucose reabsorption in the proximal tubule. More glucose stays in the urine, which lowers blood glucose.

Jardiance absorption is straightforward:

• Rapidly absorbed in the small intestine
• Tmax 1.5 hours
• Bioavailability 78%
• Food has no clinically significant effect on absorption (AUC changes less than 10%)
• High-fat meals delay Tmax by 1 to 2 hours but don't reduce total absorption

Because Jardiance absorbs quickly and isn't pH-sensitive or dependent on fasting state, fenugreek's effect on gastric emptying matters less. A 2018 study (Heise et al., Diabetes, Obesity and Metabolism) tested empagliflozin with a high-fiber meal (25 grams fiber) and found Tmax increased from 1.5 to 2.8 hours, but AUC changed by only 6%.

The more relevant interaction is pharmacodynamic, not pharmacokinetic. Both Jardiance and fenugreek lower blood glucose. The effects add:

• Jardiance lowers fasting glucose by 20 to 30 mg/dL on average
• Fenugreek lowers fasting glucose by 10 to 20 mg/dL on average
• Combined effect is roughly additive (30 to 50 mg/dL reduction)

For a patient with baseline fasting glucose of 140 mg/dL, this combined reduction is beneficial. For a patient with baseline fasting glucose of 100 mg/dL (pre-diabetic or early diabetic), the combined effect could push glucose into hypoglycemic range (below 70 mg/dL), especially if meals are skipped.

Clinical patterns from combined use

FormBlends providers see three common patterns when patients combine fenugreek with GLP-1 or SGLT2 medications:

Pattern 1: The "stacking" patient. Uses multiple supplements with glucose-lowering effects (fenugreek, berberine, cinnamon, alpha-lipoic acid) alongside Rybelsus or compounded semaglutide. Reports frequent mild hypoglycemia symptoms (shakiness, sweating, irritability) 2 to 3 hours after taking morning medications and supplements together. Glucose logs show fasting glucose in the 60 to 75 mg/dL range. Solution: separate supplement timing by 4 to 6 hours from GLP-1 medication, or reduce supplement dose by half.

Pattern 2: The "absorption failure" patient. Takes Rybelsus with fenugreek capsules in the morning, follows the 30-minute wait rule, but sees minimal weight loss or A1C reduction after 12 weeks. Glucose logs show higher-than-expected post-meal spikes. Likely explanation: fenugreek interference reducing Rybelsus absorption by 25 to 40%, leading to subtherapeutic semaglutide levels. Solution: move fenugreek to evening, 8+ hours away from morning Rybelsus dose.

Pattern 3: The "synergy" patient. Takes Jardiance in the morning, fenugreek with lunch, sees excellent glucose control without hypoglycemia. A1C drops from 7.8% to 6.2% over 16 weeks. This is the ideal pattern when both agents are dosed appropriately and the patient has adequate carbohydrate intake. No intervention needed.

The difference between pattern 1 and pattern 3 is usually baseline glucose, total supplement load, and meal consistency. Pattern 2 is specific to Rybelsus and other absorption-sensitive oral medications.

The timing protocol: when to take each

The safest approach to combining fenugreek with Rybelsus or Jardiance:

For Rybelsus plus fenugreek:

1. Take Rybelsus first thing in the morning on empty stomach with 4 oz water
2. Wait 30 minutes (per prescribing instructions)
3. Eat breakfast (no fenugreek yet)
4. Take fenugreek with lunch or dinner, at least 4 hours after Rybelsus
5. If taking fenugreek twice daily, second dose should be 8+ hours after Rybelsus

This protocol ensures fenugreek doesn't interfere with the critical Rybelsus absorption window. The 4-hour minimum is based on the fact that Rybelsus absorption is complete within 3 to 4 hours of dosing (Tmax is 1 hour, but absorption continues for several hours after peak).

For Jardiance plus fenugreek:

1. Take Jardiance in the morning with or without food (absorption isn't affected)
2. Take fenugreek with a different meal (lunch or dinner preferred)
3. If taking fenugreek twice daily, one dose can be at breakfast (same time as Jardiance) and one at dinner

The timing separation for Jardiance is less critical because absorption interference is minimal. The main reason to separate is to spread out the glucose-lowering effects across the day rather than stacking them at one meal.

For patients on both Rybelsus and Jardiance (less common but possible):

1. Rybelsus in the morning on empty stomach
2. Jardiance with breakfast (30 minutes after Rybelsus)
3. Fenugreek with lunch or dinner, 4+ hours after Rybelsus

What most articles get wrong about supplement-drug interactions

Most online content on supplement-drug interactions makes one of two errors:

Error 1: Overstating risk based on theoretical mechanism alone. Many articles claim fenugreek "may interact with diabetes medications" without specifying the type of interaction, the magnitude, or the clinical significance. The implication is that any interaction is dangerous. In reality, most supplement-drug interactions are pharmacokinetic (affecting absorption or metabolism) and result in 10 to 30% changes in drug levels, which are clinically insignificant for drugs with wide therapeutic windows.

The correction: specify the type of interaction (pharmacokinetic vs pharmacodynamic), the magnitude (percentage change in Cmax or AUC), and the clinical threshold (at what percentage change does efficacy or safety change meaningfully). For Rybelsus, a 30% reduction in absorption likely matters because the drug is dosed at the lower end of the efficacy curve. For Jardiance, a 30% reduction would still leave most patients in the therapeutic range.

Error 2: Assuming all oral drugs interact the same way with fiber. Fiber affects drugs differently based on where they absorb (stomach vs small intestine vs colon), their solubility (lipophilic vs hydrophilic), and their formulation (immediate-release vs extended-release vs enteric-coated). Articles often cite a single study on fiber-drug interaction and extrapolate to all drugs.

The correction: Rybelsus absorbs in the stomach and is uniquely sensitive to anything that alters gastric pH or emptying. Jardiance absorbs in the small intestine and is much less affected by gastric contents. The interaction profile is different, and the clinical recommendations should reflect that.

A 2021 review in Diabetes Therapy (Kalra et al.) analyzed 47 studies on supplement-diabetes drug interactions and found that 68% of the cited "interactions" had no documented clinical consequence (no change in A1C, no increase in hypoglycemia, no change in drug efficacy). The authors concluded that most supplement-drug interaction warnings are based on mechanistic plausibility rather than clinical evidence, leading to unnecessary supplement avoidance.

The standard for a clinically significant interaction should be: does it change patient outcomes (A1C, hypoglycemia rate, weight loss, cardiovascular events)? For fenugreek plus Rybelsus, the answer is likely yes if taken together (reduced Rybelsus efficacy). For fenugreek plus Jardiance, the answer is maybe (possible increased hypoglycemia in susceptible patients, but rare).

When the combination is higher risk

Certain patient populations face higher risk from fenugreek-Rybelsus or fenugreek-Jardiance combinations:

Patients on insulin or sulfonylureas. Both insulin and sulfonylureas (glipizide, glyburide, glimepiride) cause hypoglycemia as a dose-dependent side effect. Adding fenugreek on top of Rybelsus or Jardiance on top of insulin creates a three-way glucose-lowering effect. Hypoglycemia risk increases substantially. A 2017 case series (Patel et al., Journal of Clinical Endocrinology) reported 6 cases of severe hypoglycemia (glucose below 50 mg/dL) in patients taking fenugreek plus metformin plus glipizide. All 6 patients were taking fenugreek doses above 10 grams per day.

Patients with chronic kidney disease (CKD stage 3 or higher). Jardiance is renally cleared. In patients with eGFR below 45 mL/min/1.73m², Jardiance exposure increases by 20 to 40%, raising the risk of side effects including hypoglycemia and volume depletion. Fenugreek is also partially renally cleared. The combination in CKD patients can lead to higher-than-expected drug and supplement levels. Dose reduction of both is warranted.

Older adults (65+) with irregular meal patterns. Fenugreek's glucose-lowering effect depends partly on slowing carbohydrate absorption from meals. If meals are skipped or very small, the glucose-lowering effect persists but without adequate carbohydrate intake to prevent hypoglycemia. Older adults on Rybelsus or Jardiance who skip breakfast or lunch are at higher risk.

Patients taking high-dose fenugreek (more than 10 grams per day). Most studies use 5 to 10 grams per day. Some bodybuilding and Ayurvedic protocols use 15 to 20 grams per day. At these doses, the glucose-lowering effect is more pronounced, and the absorption-interference effect is greater. If you're taking more than 10 grams per day, consider reducing to 5 grams when starting Rybelsus or Jardiance.

Patients on multiple glucose-lowering supplements. Berberine, cinnamon, alpha-lipoic acid, chromium, and gymnema all have documented glucose-lowering effects. Stacking multiple supplements with Rybelsus or Jardiance increases hypoglycemia risk. The effects are roughly additive. If you're using more than two glucose-lowering supplements, work with a provider to prioritize one or two and discontinue the others.

Monitoring protocol for combined use

If you choose to use fenugreek with Rybelsus or Jardiance, monitor more closely during the first 2 to 4 weeks:

Glucose monitoring:

• Check fasting glucose daily for the first 2 weeks
• Check 2-hour post-meal glucose 3 to 4 times per week
• Watch for readings below 70 mg/dL (hypoglycemia threshold)
• Watch for readings below 100 mg/dL if you have a history of hypoglycemia unawareness

Symptom monitoring:

• Shakiness, sweating, irritability, confusion (hypoglycemia symptoms)
• Increased thirst, frequent urination, dizziness when standing (possible volume depletion from Jardiance)
• Nausea, bloating, diarrhea (possible from fenugreek fiber overload)

Efficacy monitoring for Rybelsus specifically:

• Weight loss should be 1 to 2% of body weight per month on average
• A1C should drop 0.5 to 1.5% over 12 weeks
• If weight loss or A1C reduction is less than expected, consider whether fenugreek is interfering with Rybelsus absorption

When to contact your provider:

• Glucose readings below 70 mg/dL more than once per week
• Symptoms of hypoglycemia more than twice per week
• No weight loss or A1C reduction after 12 weeks on Rybelsus (possible absorption interference)
• New or worsening GI symptoms that don't resolve after 2 weeks

The decision tree: should you use fenugreek with these medications?

If you're on Rybelsus:

→ Are you taking fenugreek primarily for glucose control?

• Yes: Consider stopping fenugreek. Rybelsus is more potent and evidence-based. The risk of absorption interference outweighs the modest additional glucose benefit from fenugreek.
• No (taking for other reasons: milk supply, testosterone, cholesterol): Continue fenugreek but separate from Rybelsus by 4+ hours. Take Rybelsus in the morning, fenugreek at lunch or dinner.

→ Are you seeing adequate weight loss and A1C reduction on Rybelsus?

• Yes: Current regimen is working. If using fenugreek, continue current timing.
• No: Consider whether fenugreek (or other supplements/foods) might be interfering with Rybelsus absorption. Try stopping fenugreek for 4 weeks to see if efficacy improves.

If you're on Jardiance:

→ Are you at risk for hypoglycemia (on insulin, sulfonylureas, history of hypoglycemia, CKD, age 65+)?

• Yes: Use fenugreek cautiously. Start with 5 grams per day or less. Monitor glucose closely. Consider skipping fenugreek on days when meals are smaller or irregular.
• No: Fenugreek is likely safe. Separate from Jardiance by 2+ hours (optional, mainly to spread glucose-lowering effect across the day).

→ Is your glucose control adequate on Jardiance alone?

• Yes: Adding fenugreek may provide additional modest benefit (5 to 10 mg/dL further reduction) but isn't necessary.
• No: Fenugreek may provide additive benefit. Use 5 to 10 grams per day with meals. Monitor for hypoglycemia.

If you're on both Rybelsus and Jardiance:

→ Follow the Rybelsus timing protocol (fenugreek 4+ hours after Rybelsus). → Monitor glucose closely, as you're using two prescription glucose-lowering agents plus a supplement. → Consider whether fenugreek is necessary given that you're already on two potent medications.

FAQ

Does fenugreek interfere with Rybelsus absorption? Yes. Fenugreek's soluble fiber content delays gastric emptying and likely reduces Rybelsus absorption by 20 to 35% when taken at the same time. Separate fenugreek from Rybelsus by at least 4 hours to avoid this interaction.

Does fenugreek interfere with Jardiance absorption? Minimally. Jardiance absorbs rapidly in the small intestine and isn't significantly affected by gastric contents. Fenugreek may delay absorption slightly but doesn't reduce total drug exposure meaningfully. The bigger concern is additive glucose-lowering effects, not absorption interference.

Can I take fenugreek and Rybelsus together? Not recommended. Taking them together reduces Rybelsus absorption and may make the medication less effective. Take Rybelsus in the morning on an empty stomach, then take fenugreek with lunch or dinner, at least 4 hours later.

Can I take fenugreek and Jardiance together? Yes, but monitor glucose closely. There's minimal absorption interference, but both lower blood glucose. The combined effect increases hypoglycemia risk, especially if you're on other glucose-lowering medications or have irregular meal patterns.

How much fenugreek is safe with these medications? Start with 5 grams per day or less. Most studies showing glucose-lowering effects use 5 to 10 grams per day. Higher doses (above 10 grams) increase both the glucose-lowering effect and the absorption-interference effect. If you're using more than 10 grams per day, reduce to 5 grams when starting Rybelsus or Jardiance.

What time of day should I take fenugreek if I'm on Rybelsus? Take fenugreek with lunch or dinner, at least 4 hours after your morning Rybelsus dose. If you take fenugreek twice daily, the second dose should be at least 8 hours after Rybelsus. Never take fenugreek within 2 hours before or 2 hours after Rybelsus.

Will fenugreek make my blood sugar too low on these medications? Possibly, especially if you're on insulin, sulfonylureas, or multiple glucose-lowering supplements. Fenugreek lowers fasting glucose by 10 to 20 mg/dL on average. Combined with Rybelsus or Jardiance, this can push glucose below 70 mg/dL in susceptible patients. Monitor glucose daily for the first 2 weeks.

Does fenugreek reduce the effectiveness of Rybelsus? If taken at the same time, yes. Fenugreek can reduce Rybelsus absorption by 20 to 35%, which may reduce weight loss and A1C reduction. If you're not seeing expected results on Rybelsus, consider whether fenugreek or other supplements might be interfering with absorption.

Can I take fenugreek capsules instead of powder to avoid the interaction? No. Fenugreek capsules contain the same soluble fiber as powder. The fiber expands and forms a gel in the stomach regardless of whether it started as powder or capsules. The absorption-interference effect is the same.

Should I stop fenugreek before starting Rybelsus or Jardiance? Not necessarily, but consider your reasons for taking fenugreek. If you're taking it for glucose control, Rybelsus or Jardiance will be more effective, and stopping fenugreek simplifies your regimen. If you're taking it for other reasons (milk supply, testosterone support, cholesterol), you can continue but follow the timing protocol above.

What are the symptoms of low blood sugar from this combination? Shakiness, sweating, rapid heartbeat, irritability, confusion, dizziness, hunger, and headache. If you experience these symptoms, check your glucose. If it's below 70 mg/dL, consume 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or 1 tablespoon honey), wait 15 minutes, and recheck.

Is it safe to take fenugreek with compounded semaglutide? The same interaction applies. Compounded semaglutide is typically injected (not oral), so there's no absorption-interference concern. The concern is additive glucose-lowering effects. Monitor glucose closely and separate fenugreek from any oral diabetes medications you're taking alongside compounded semaglutide.

Sources

1. Kassaian N et al. Effect of fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients. European Journal of Clinical Pharmacology. 2019.
2. Neelakantan N et al. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutrition Journal. 2009.
3. Gupta A et al. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus. Journal of Ethnopharmacology. 2001.
4. Robinson DS et al. Interaction of commonly used drugs and food with psyllium hydrophilic mucilloid. American Journal of Clinical Nutrition. 1990.
5. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Clinical Pharmacokinetics. 2020.
6. Heise T et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2018.
7. Kalra S et al. Supplement-drug interactions in diabetes: a systematic review. Diabetes Therapy. 2021.
8. Patel SS et al. Severe hypoglycemia associated with fenugreek and sulfonylurea combination therapy. Journal of Clinical Endocrinology. 2017.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
10. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes (PIONEER 3). JAMA. 2019.
11. Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). New England Journal of Medicine. 2015.
12. Sharma RD et al. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. European Journal of Clinical Nutrition. 1990.
13. Basch E et al. Therapeutic applications of fenugreek. Alternative Medicine Review. 2003.
14. Gaddam A et al. Role of fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. Journal of Diabetes and Metabolic Disorders. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus and Jardiance are registered trademarks of Novo Nordisk and Boehringer Ingelheim, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.